(Total Views: 465)
Posted On: 12/04/2019 11:38:36 AM
Post# of 154803
Z_Smith ,-
yes our competition , Ibalizumab , CD4 inhibitor .
I will just say few things about HIV treatment here , first , price with Ibalizumab is 118,000.00 a year plus ( my understanding ) IV treatment ..with more side effects than with Leronlimb .....
IV treatment every two weeks ..
They do not consider mono , only combo ...and no candidate for PrEP ...
I exchanged few e-mails couple of years ago with Dr Chen from TaiMed ...
and that what he told me about mono ...
In phase 3 , they had 40 patients , one drop out because of Immune Reconstitution Inflammatory Syndrome ..
There were deaths during treatment all together , not necessary due to Ibalizumab . ...
After study were finished , it was approved for MDR -3 as every 2 weeks IV treatment , with efficacy of 43%
We are much better in my opinion ,
We had in our combo study ( 50 or 52 patients ) ....MDR-3 patients , and MDR-2 without choices ,
none of our patients died or dropped from the study,
and our efficacy is 81% with 350 mg , and not one serious side effect...
And treatment is SC and not IV, very , very big difference to patients..
and 81% efficacy with 350 mg , is much better than 43% ...
Personally for R5 HIV strain HIV , I don't believe Ibalizumab is really a big competition to Leronlimab ...
All IMO.
yes our competition , Ibalizumab , CD4 inhibitor .
I will just say few things about HIV treatment here , first , price with Ibalizumab is 118,000.00 a year plus ( my understanding ) IV treatment ..with more side effects than with Leronlimb .....
IV treatment every two weeks ..
They do not consider mono , only combo ...and no candidate for PrEP ...
I exchanged few e-mails couple of years ago with Dr Chen from TaiMed ...
and that what he told me about mono ...
In phase 3 , they had 40 patients , one drop out because of Immune Reconstitution Inflammatory Syndrome ..
There were deaths during treatment all together , not necessary due to Ibalizumab . ...
After study were finished , it was approved for MDR -3 as every 2 weeks IV treatment , with efficacy of 43%
We are much better in my opinion ,
We had in our combo study ( 50 or 52 patients ) ....MDR-3 patients , and MDR-2 without choices ,
none of our patients died or dropped from the study,
and our efficacy is 81% with 350 mg , and not one serious side effect...
And treatment is SC and not IV, very , very big difference to patients..
and 81% efficacy with 350 mg , is much better than 43% ...
Personally for R5 HIV strain HIV , I don't believe Ibalizumab is really a big competition to Leronlimab ...
All IMO.
(2)
(0)
